Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell receptor beta variable 9 (TRBV9) is a protein segment that constitutes the variable domain of the beta chain of the T cell receptor (TCR) complex. The TCR, particularly the alpha-beta heterodimer, is a key component of the adaptive immune system, responsible for recognizing and binding to antigenic peptides presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells. The TRBV9 gene encodes the variable region of the TCR beta chain, contributing to the diversity of the T cell repertoire through V(D)J recombination in the thymus. This diversity allows effective immune surveillance against a wide array of pathogens. Upon recognition of peptide-MHC by the TCR, signal transduction is mediated through associated CD3 molecules, initiating T cell activation, proliferation, and effector functions. TRBV9 and other TCR Vβ chains play critical roles in antigen specificity, shaping immune responses, and have clinical importance in disease contexts such as infection, cancer, and autoimmunity[1][2][7].
Recognition of peptide-MHC complexes leading to T cell activation via CD3 signaling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor beta variable 9 (TRBV9).